awmsg logo



velaglucerase alfa (VPRIV®)


Reference No. 571

Publication date:
25/07/2014


Appraisal information

velaglucerase alfa (VPRIV®) 400 units powder for solution for infusion


Company: Shire Pharmaceuticals Ltd
BNF category: Nutrition and blood
NMG meeting date: 14/05/2014
AWMSG meeting date: 11/06/2014
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1214
Ministerial ratification: 24/07/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Velaglucerase alfa (VPRIV®) is recommended as an option for use within NHS Wales for long-term enzyme replacement therapy in patients with type 1 Gaucher disease. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download